Bellevue Asset Management’s Thermo Fisher Scientific TMO Stock Holding History

Bellevue Asset Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-97	Closed	-$50.5K	–	502
2024 Q4	$50.5K	Hold	97	–	–	0.03%	155
2024 Q3	$60K	Hold	97	–	–	0.03%	143
2024 Q2	$53.6K	Hold	97	–	–	0.03%	143
2024 Q1	$56.4K	Hold	97	–	–	0.03%	139
2023 Q4	$51.5K	Hold	97	–	–	0.05%	148
2023 Q3	$49.1K	Hold	97	–	–	0.03%	141
2023 Q2	$50.6K	Hold	97	–	–	0.03%	148
2023 Q1	$55.9K	Hold	97	–	–	0.04%	135
2022 Q4	$53K	Hold	97	–	–	0.04%	144
2022 Q3	$50K	Hold	97	–	–	0.04%	149
2022 Q2	$53K	Hold	97	–	–	0.04%	150
2022 Q1	$58K	Hold	97	–	–	0.04%	156
2021 Q4	$65K	Hold	97	–	–	0.04%	151
2021 Q3	$56K	Hold	97	–	–	0.03%	170
2021 Q2	$49K	Hold	97	–	–	0.03%	177
2021 Q1	$44K	Hold	97	–	–	0.03%	188
2020 Q4	$50K	Hold	97	–	–	0.03%	172
2020 Q3	$43K	Hold	97	–	–	0.03%	173
2020 Q2	$35K	Hold	97	–	–	0.04%	200
2020 Q1	$33K	Hold	97	–	–	0.03%	210
2019 Q4	$32K	Buy	+97	New	+$29.4K	0.02%	208

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bellevue Asset Management's TMO Position: Q1 2025 in Review

Bellevue Asset Management sold out of Thermo Fisher Scientific (TMO) in Q1 2025, closing a stake of 97 shares — an estimated $50.5K sold.

Bellevue Asset Management first reported a position in TMO in Q4 2019 and held it in 21 quarters. The position peaked at $65K in Q4 2021. 2,578 funds tracked by Wall St. Rank hold TMO as of Q1 2025.

Bellevue Asset Management reported no remaining Thermo Fisher Scientific position as of Q1 2025 after selling out during the quarter.
Bellevue Asset Management sold 97 Thermo Fisher Scientific shares in Q1 2025, an estimated $50.5K.
Bellevue Asset Management first reported a position in Thermo Fisher Scientific in Q4 2019 and held it in 21 quarters.
Bellevue Asset Management's Thermo Fisher Scientific position peaked at $65K in Q4 2021.
2,578 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2025.

Based on Bellevue Asset Management's 13F filing for Q1 2025, filed 28 Apr 2025.